Double modulation with methotrexate and L-leucovorin of Weekly 24 - hour fluorouracil infusion in fluorouracil - refractory colorectal cancer

Marco Colleoni, Patrizia Nelli, Giovanni Vicario, Francesca Pancheri, Gigliola Sgarbossa, Paolo Manente

Research output: Contribution to journalArticlepeer-review

Abstract

No effective second-line therapy has been developed for patients with metastatic colorectal cancer progressive after than fluorouracil(Fu)-containing chemotherapy. Encouraging results have been reported with weekly 24-hour FU infusion. The aim of this study was to rest the activity of weekly FU infusion plus modulation with methotrexate and L-leucovorin in pretreated colorectal cancer patients. Seventeen patients with metastatic colorectal carcinoma were treated with methotrexate (40 mg/m2 on day 1), L-leucovorin (100 mg/m2 as a 4-hour infusion on day 2), and FU (2,600 mg/m2 as a 24-hour infusion on day 2). All patients had measurable disease and a performance status of ECOG 0-2. Two of the 17 evaluable patients achieved partial remission (12%; 95% confidence interval 2-24%), 9 had stable disease, and 6 progressive disease, Median time to progression was 4 months (range, 2-8) and median survival was 7 months (range, 3-12+. Toxicity was generally mild or moderate and consisted of mucositis, diarrhea and neutropenia. Pretreated patients with metastatic colorectal carcinoma benefit only marginally from this treatment schedule.

Original languageEnglish
Pages (from-to)3101-3104
Number of pages4
JournalAnticancer Research
Volume16
Issue number5 B
Publication statusPublished - Sep 1996

Keywords

  • Fluorouracil infusion
  • Leucovorin
  • Methotrexate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Double modulation with methotrexate and L-leucovorin of Weekly 24 - hour fluorouracil infusion in fluorouracil - refractory colorectal cancer'. Together they form a unique fingerprint.

Cite this